Test directory: JAK2, V617F Mut. w/Reflex Exon 12

Ordering Code6613
Test NameJAK2, V617F Mut. w/Reflex Exon 12
AliasJAK2 (V617F) Mutation by ddPCR, Qualitative with
Reflex to JAK2 Exon 12 Mutation Analysis by PCR
Preferred SpecimenWhole Blood
Preferred ContainerEDTA, K2 (Lavender)
Optimum Volume5 mL
Collection InstructionsPerform collection on Monday through Thursday only.
Transport RequirementsOahu: Refrigerated
Airline: Refrigerated
Specimen StabilityAmbient: Not Stable
Refrigerated: 7 Days
Frozen: Not Stable
Rejection CriteriaPlasma, Serum, FFPE tissue blocks/slides, or fresh or frozen tissue, Specimens collected in anticoagulants other than
EDTA, Clotted or grossly hemolyzed specimens
Avail. StatNO
Analytic Time14-21 Days
MethodologyDroplet Digital Polymerase Chain Reaction/Polymerase
Chain Reaction
Reference Lab ARUP Laboratories

Reference range(s)

The reference ranges listed below are valid on this date of January 15, 2025.
ComponentAgeMale NormMale Critical LowMale Critical HighFemale NormFemale Critical HighFemale Critical LowUnitsAdd'l info
JAK2 Qual, SourceALLSee report.
JAK2 Gene, V617F Mutation, Qual.ALL

INTERPRETIVE...
INTERPRETIVE INFORMATION
This assay is designed to detect the point mutation c.1849G>T (V617F) of the JAK2 gene. JAK2 V617F mutations are present in patients with myeloproliferative neoplasms

Methodology: DNA from whole blood or bone marrow specimens is amplified in an allele-specific droplet digital PCR (ddPCR) multiplex reaction targeting the JAK2 c.1849G>T single nucleotide mutation encoding the V617F mutation. The limit of detection for this assay is 0.5 percent mutated alleles

Limitations: Variants in genes other than JAK2 are not detected. JAK2 variants other than V617F (c.1849G>T) are not reported. Samples with JAK2
V617F mutations below the limit of detection are not reported

Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy

This test was developed and its performance characteristics determined by ARUP Laboratories
It has not been cleared or approved by the U.S
Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes

See report.
Note1

Note1:


INTERPRETIVE INFORMATION
This assay is designed to detect the point mutation c.1849G>T (V617F) of the JAK2 gene. JAK2 V617F mutations are present in patients with myeloproliferative neoplasms

Methodology: DNA from whole blood or bone marrow specimens is amplified in an allele-specific droplet digital PCR (ddPCR) multiplex reaction targeting the JAK2 c.1849G>T single nucleotide mutation encoding the V617F mutation. The limit of detection for this assay is 0.5 percent mutated alleles

Limitations: Variants in genes other than JAK2 are not detected. JAK2 variants other than V617F (c.1849G>T) are not reported. Samples with JAK2
V617F mutations below the limit of detection are not reported

Results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy

This test was developed and its performance characteristics determined by ARUP Laboratories
It has not been cleared or approved by the U.S
Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes

See report..